Asarina Pharma AB

Equities

ASAP

SE0011641794

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:20:03 2024-04-24 am EDT			5-day change	1st Jan Change
0.95 ^SEK	+1.50%		+6.26%	+7.95%

Feb. 27	Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Asarina Pharma publ : Annual Report for 2019 released

April 16, 2020 at 05:10 am EDT

Asarina Pharma AB today announces that its Annual Report for 2019 is now available on the company's website.

Contact:

Peter Nordkild

Tel: +45 25 47 16 46

Email: peter.nordkild@asarinapharma.com

About Asarina Pharma

We are a Swedish biotech company developing Sepranolone, the world's first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years' research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women's Health company.

This information is information that Asarina Pharma AB (publ.) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, on April 14, 2020 at 08:00 CET.

Latest news about Asarina Pharma AB

Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	23-05-05	CI
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Asarina Pharma Completes Recruitment For Clinical Study On Tourette Syndrome	22-10-14	MT
Asarina Pharma Completes Recruitment of Patients to its Phase IIa Clinical Study in Tourette Syndrome	22-10-14	CI
Asarina Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Asarina Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-25	CI
Asarina Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Asarina Pharma AB Announces That `First Patient First Visit' Has Taken Place in Its Phase Ii A Clinical Study in Tourette Syndrome At Bispebjerg University Hospital, Copenhagen	22-02-16	CI
Asarina Pharma Receives Final Approval for Phase IIa Tourette Study	21-12-22	CI
Asarina Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-25	CI
Pmdd Phase Iib Study, Including Post-Hoc Analysis Showing ‘Significant Treatment Effect	21-09-28	CI
Asarina Pharma Announces Administrative Backlog At Public Authority Causes Short-Term Delay in Tourette Study	21-09-16	CI
Asarina Pharma AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-19	CI
Asarina Pharma Reports Topline Results in Phase IIa Menstrual Migraine Study	21-06-23	CI
The US Patent and Trademark Office Grants Asarina Pharma's Patent for Sepranolone for the Treatment of Tourette, Obsessive-Compulsive Disorder and Pathological Gambling	21-06-08	CI
Asarina Pharma AB Receives Approval of CTA for Phase IIa Tourette Study	21-05-19	CI
Asarina Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-18	CI
Asarina Pharma AB Confirms New Preclinical Study That Sepranolone Suppresses Tics in Tourette Syndrome	21-02-11	CI
Asarina Pharma AB Publ Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-25	CI
Asarina Pharma AB Reaches Full Patient Enrolment in Its Phase Iia Menstrual Migraine (Mm) Study	20-09-30	CI
Asarina Pharma AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-19	CI
Asarina Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-26	CI

Chart Asarina Pharma AB

Duration

Period

More charts

Company Profile

Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of womenâs health. The Companyâs main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Companyâs main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASARINA PHARMA AB	+7.95%	1.96M
VERTEX PHARMACEUTICALS INCORPORATED	-1.55%	105B
REGENERON PHARMACEUTICALS, INC.	+3.66%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.38%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-21.30%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.07%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.74%	10.99B

Bio Therapeutic Drugs